Related Experiment Video
Updated: Jan 20, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Pregnancy after cerebral venous thrombosis
Maria Abbattista1, Marco Capecchi1, Ida Martinelli1
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan, Italy.
Pregnancy outcome in women with previous cerebral vein thrombosis (CVT) on antithrombotic prophylaxis with low-molecular weight heparin (LMWH) is largely unknown. Aims of this study were to evaluate the risk of recurrent VTE, bleeding and pregnancy outcome in a cohort of pregnant women on LMWH after a first episode of CVT. To estimate the efficacy of LMWH in the prevention of obstetrical complications we compared pregnancies before (without LMWH) with pregnancies after (with LMWH) CVT in 25 women. Two recurrent thrombosis (3.2%, 95% CI 0.9-10.9%) and no bleeding episodes were observed in 63 pregnant women on LMWH. The risk of miscarriage was 13.5% (95% CI 6.1-24.8%) and that of late obstetrical complications 19.2% (95% CI 10.2-31.6%), independently of previous history of obstetrical complications and carriership of thrombophilia abnormalities. A double prevalence of terminations was observed in patients with thrombophilia than in those without. In conclusion, women with previous CVT on LMWH prophylaxis during pregnancy have a low risk of recurrent thrombosis and bleeding, but an increased risk of obstetrical complications.
Pregnancy outcome in women with previous cerebral vein thrombosis (CVT) on antithrombotic prophylaxis with low-molecular weight heparin (LMWH) is largely unknown. Aims of this study were to evaluate the risk of recurrent VTE, bleeding and pregnancy outcome in a cohort of pregnant women on LMWH after a first episode of CVT. To estimate the efficacy of LMWH in the prevention of obstetrical complications we compared pregnancies before (without LMWH) with pregnancies after (with LMWH) CVT in 25 women. Two recurrent thrombosis (3.2%, 95% CI 0.9-10.9%) and no bleeding episodes were observed in 63 pregnant women on LMWH. The risk of miscarriage was 13.5% (95% CI 6.1-24.8%) and that of late obstetrical complications 19.2% (95% CI 10.2-31.6%), independently of previous history of obstetrical complications and carriership of thrombophilia abnormalities. A double prevalence of terminations was observed in patients with thrombophilia than in those without. In conclusion, women with previous CVT on LMWH prophylaxis during pregnancy have a low risk of recurrent thrombosis and bleeding, but an increased risk of obstetrical complications.
Related Concept Videos
04:40Venous Thrombosis Assay in a Mouse Model of Cancer
Venous Thrombosis I: Introduction
06:03Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
06:45Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
